Publicação: Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1
dc.contributor.author | Boelen, Lies | |
dc.contributor.author | Debebe, Bisrat | |
dc.contributor.author | Silveira, Marcos [UNESP] | |
dc.contributor.author | Salam, Arafa | |
dc.contributor.author | Makinde, Julia | |
dc.contributor.author | Roberts, Chrissy H. | |
dc.contributor.author | Wang, Eddie C.Y. | |
dc.contributor.author | Frater, John | |
dc.contributor.author | Gilmour, Jill | |
dc.contributor.author | Twigger, Katie | |
dc.contributor.author | Ladell, Kristin | |
dc.contributor.author | Miners, Kelly L. | |
dc.contributor.author | Jayaraman, Jyothi | |
dc.contributor.author | Traherne, James A. | |
dc.contributor.author | Price, David A. | |
dc.contributor.author | Qi, Ying | |
dc.contributor.author | Martin, Maureen P. | |
dc.contributor.author | Macallan, Derek C. | |
dc.contributor.author | Thio, Chloe L. | |
dc.contributor.author | Astemborski, Jacquie | |
dc.contributor.author | Kirk, Gregory | |
dc.contributor.author | Donfield, Sharyne M. | |
dc.contributor.author | Buchbinder, Susan | |
dc.contributor.author | Khakoo, Salim I. | |
dc.contributor.author | Goedert, James J. | |
dc.contributor.author | Trowsdale, John | |
dc.contributor.author | Carrington, Mary | |
dc.contributor.author | Kollnberger, Simon | |
dc.contributor.author | Asquith, Becca | |
dc.contributor.institution | Imperial College London | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.contributor.institution | University of London | |
dc.contributor.institution | International AIDS Vaccine Initiative Human Immunology Laboratory | |
dc.contributor.institution | London School of Hygiene and Tropical Medicine | |
dc.contributor.institution | Cardiff University School of Medicine | |
dc.contributor.institution | University of Oxford | |
dc.contributor.institution | Oxford NIHR Biomedical Research Centre | |
dc.contributor.institution | University of Cambridge | |
dc.contributor.institution | Frederick National Laboratory for Cancer Research | |
dc.contributor.institution | Johns Hopkins University | |
dc.contributor.institution | Rho | |
dc.contributor.institution | San Francisco Department of Public Health | |
dc.contributor.institution | University of Southampton | |
dc.contributor.institution | National Cancer Institute | |
dc.contributor.institution | MIT and Harvard | |
dc.date.accessioned | 2019-10-06T16:55:02Z | |
dc.date.available | 2019-10-06T16:55:02Z | |
dc.date.issued | 2018-01-01 | |
dc.description.abstract | Killer cell immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer cells, where they play a key role in the regulation of innate immune responses. Recent studies show that inhibitory KIRs can also affect adaptive T cell–mediated immunity. In mice and in human T cells in vitro, inhibitory KIR ligation enhanced CD8+ T cell survival. To investigate the clinical relevance of these observations, we conducted an extensive immunogenetic analysis of multiple independent cohorts of HIV-1–, hepatitis C virus (HCV)–, and human T cell leukemia virus type 1 (HTLV-1)–infected individuals in conjunction with in vitro assays of T cell survival, analysis of ex vivo KIR expression, and mathematical modeling of host-virus dynamics. Our data suggest that functional engagement of inhibitory KIRs enhances the CD8+ T cell response against HIV-1, HCV, and HTLV-1 and is a significant determinant of clinical outcome in all three viral infections. | en |
dc.description.affiliation | Department of Medicine Imperial College London | |
dc.description.affiliation | Faculty of Engineering São Paulo State University—UNESP | |
dc.description.affiliation | Institute for Infection and Immunity St. George’s University of London | |
dc.description.affiliation | International AIDS Vaccine Initiative Human Immunology Laboratory | |
dc.description.affiliation | Clinical Research Department London School of Hygiene and Tropical Medicine | |
dc.description.affiliation | Divi-sion of Infection and Immunity Cardiff University School of Medicine | |
dc.description.affiliation | Nuffield Department of Medicine University of Oxford | |
dc.description.affiliation | Oxford NIHR Biomedical Research Centre | |
dc.description.affiliation | Immunology Division Department of Pathology University of Cambridge | |
dc.description.affiliation | Cancer and Inflammation Program Leidos Biomedical Research Inc. Frederick National Laboratory for Cancer Research | |
dc.description.affiliation | Johns Hopkins University | |
dc.description.affiliation | Rho | |
dc.description.affiliation | San Francisco Department of Public Health | |
dc.description.affiliation | Faculty of Medicine University of Southampton | |
dc.description.affiliation | Division of Cancer Epidemiology and Genetics National Cancer Institute | |
dc.description.affiliation | Ragon Institute of MGH, MIT and Harvard | |
dc.description.affiliationUnesp | Faculty of Engineering São Paulo State University—UNESP | |
dc.description.sponsorship | Wisconsin Turfgrass Association | |
dc.description.sponsorship | National Institutes of Health | |
dc.description.sponsorship | Wellcome Trust | |
dc.description.sponsorship | Institute for National Strategic Studies | |
dc.description.sponsorship | Leukemia and Lymphoma Research | |
dc.description.sponsorship | Seventh Framework Programme | |
dc.description.sponsorship | Horizon 2020 | |
dc.description.sponsorship | Medical Research Council Canada | |
dc.description.sponsorship | National Institute on Drug Abuse | |
dc.description.sponsorship | National Institute of Child Health and Human Development | |
dc.description.sponsorshipId | Wisconsin Turfgrass Association: 090323/Z/09/Z | |
dc.description.sponsorshipId | National Institutes of Health: 100326Z/12/Z | |
dc.description.sponsorshipId | Wellcome Trust: 103865Z/14/Z | |
dc.description.sponsorshipId | Institute for National Strategic Studies: 105609/Z/14/Z | |
dc.description.sponsorshipId | Leukemia and Lymphoma Research: 15012 | |
dc.description.sponsorshipId | Seventh Framework Programme: 317040 | |
dc.description.sponsorshipId | Horizon 2020: 695551 | |
dc.description.sponsorshipId | Medical Research Council Canada: G1001052 | |
dc.description.sponsorshipId | Medical Research Council Canada: J007439 | |
dc.description.sponsorshipId | National Institute on Drug Abuse: K24-AI118591 | |
dc.description.sponsorshipId | Medical Research Council Canada: MR/L018373/L | |
dc.description.sponsorshipId | Medical Research Council Canada: MR/M019829/1 | |
dc.description.sponsorshipId | Medical Research Council Canada: MR/P001602/1 | |
dc.description.sponsorshipId | National Institutes of Health: R01 DA13324 | |
dc.description.sponsorshipId | National Institute on Drug Abuse: R01-DA-12568 | |
dc.description.sponsorshipId | National Institute of Child Health and Human Development: R01-HD-41224 | |
dc.description.sponsorshipId | National Institute on Drug Abuse: U01-DA-036297 | |
dc.identifier | http://dx.doi.org/10.1126/sciimmunol.aao2892 | |
dc.identifier.citation | Science Immunology, v. 3, n. 29, 2018. | |
dc.identifier.doi | 10.1126/sciimmunol.aao2892 | |
dc.identifier.issn | 2470-9468 | |
dc.identifier.lattes | 8286209184527011 | |
dc.identifier.scopus | 2-s2.0-85056420369 | |
dc.identifier.uri | http://hdl.handle.net/11449/189875 | |
dc.language.iso | eng | |
dc.relation.ispartof | Science Immunology | |
dc.rights.accessRights | Acesso aberto | |
dc.source | Scopus | |
dc.title | Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1 | en |
dc.type | Artigo | |
dspace.entity.type | Publication | |
unesp.author.lattes | 8286209184527011 | |
unesp.department | Engenharia Mecânica - FEB | pt |